Catheter Infections-A Deadly and Costly Problem
The Centers for Disease Control has identified catheter-related bloodstream infections (CRBSI) as 1 of its 7 major healthcare challenges because of an estimated 200,000 to 400,000 episodes annually in the United States. The Centers for Medicare and Medicaid Services (CMS) reports the annual healthcare cost for treating CRBSI exceeds $3 billion, with over $1.5B going toward treating hemodialysis CRBSI.
Pursuit Vascular's ClearGuard™ - A Promising Solution
Pursuit Vascular, Inc. is developing a unique medical device to reduce CRBSI in order to:
- Improve patient outcomes
- Enhance patient health
- Reduce hospitalizations
- Save lives
- Provide substantial savings to worldwide healthcare systems
Pursuit Vascular is based in Minnesota and currently has three patents pending for the ClearGuard™.
